Objective: The use of GnRH antagonist versus GnRH agonist in poor responder for patient undergoing ovarian hyperstimulation and in vitro-fertilization was compared. Materials and Methods: In this study, 23 patients underwent ovarian hyperstimulation with recombinant FSH followed by the use of GnRH antagonist (Cetrorelix) 0.25mg during the late Follicular Phase. These patients were compared to 2...

The use of progesterone for luteal support in stimulated cycles for in-vitro fertilization is well established. However, the benefits of the addition of estradiol are still controversial. The aim of this study was to compare ongoing pregnancy rates in patients stimulated with recombinant follicle stimulating hormone and gonadotrophin releasing hormone antagonist for in vitro fertilization, who ...

type 2 receptors for vascular endothelial growth factor are believed to be involved in the pathophysiology of ovarian hyperstimulation syndrome (ohss). the objective of this study was to examine the preventive effects of cabergoline on ohss and its complications. the study is a non randomized clinical trial conducted in 2006-2008 on 75 patients, which were at risk of ohss and underwent assisted...

BACKGROUND The objective of this study was to assess the psychological implications of mild ovarian stimulation combined with single embryo transfer (SET) during a first IVF cycle. METHODS We conducted a randomized controlled two-centre trial. Three hundred and ninety-one couples were randomized to undergo either mild ovarian stimulation with GnRH antagonist co-treatment and SET (n=199) or co...

BACKGROUND Fragile X syndrome is associated with low ovarian reserve and poor ovarian response. The aim of this study was to investigate whether CGG repeats on the fragile X mental retardation 1 (FMR1) gene have predictive value for ovarian response to stimulation with gonadotrophins and for clinical outcome in our oocyte donation program. METHODS Oocyte donor candidates were selected accordi...

Bemfola (follitropin alfa) (Finox AG, Switzerland), a new recombinant FSH, has comparable pharmacological profile to that of Gonal-f (Merck Serono, Germany), the current standard for ovarian stimulation. A randomized, multi-centre, Phase 3 study in women undergoing IVF or intracytoplasmic sperm injection (n = 372) showed yielding similar efficacy and safety profiles Gonal-f. Women aged 20–38 ye...

background: clomiphene citrate (cc) an agonist and antagonist of estrogen, is the first line treatment in ovarian stimulation. anti-estrogenic effect of cc in endometrial thickness and cervical mucus has negative effect on pregnancy rate. letrozole is an aromatase inhibitor has been seen that has acceptable pregnancy rate compared to cc. objective: the aim of this study was to compare the effic...

BACKGROUND Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells. We investigated whether LPA could also directly promote ovarian tumor growth by increasing the level of cyclin D1, a key G1-phase checkpoint regulator, w...

BACKGROUND Serum androgen levels correlate with ovarian sensitivity to follicle-stimulating hormone (FSH) but in practice, standard baseline serum testosterone (T) levels prior to in-vitro fertilization (IVF) may not be the most appropriate marker for determination. METHODS Infertile women enrolled in an IVF programme were included in this study. Serum T and Delta4-androstenedione (A), and th...